Overview

Pharmacogenetic Approach to Anti-platelet Therapy for the Treatment of ST-segment Elevation Myocardial Infarction (STEMI)

Status:
Completed
Trial end date:
2013-03-01
Target enrollment:
0
Participant gender:
All
Summary
The objective of the RAPID STEMI study is to evaluate the feasibility, efficacy, and safety of a pharmacogenetic approach to anti-platelet therapy for the treatment of ST-segment elevation myocardial infarction (STEMI) patients following percutaneous coronary intervention (PCI) using point-of-care genetic testing for the CYP2C19*2, *17, and ABCB1 3435 C>T alleles.
Phase:
Phase 2/Phase 3
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Ottawa Heart Institute Research Corporation
Collaborator:
Spartan Bioscience Inc.
Treatments:
Clopidogrel
Prasugrel Hydrochloride
Ticlopidine
Criteria
Inclusion Criteria:

- Males and Females between the ages of 18 and 75 years

- STEMI patients treated with percutaneous coronary intervention

- Able to provide informed consent

- Able to comply with assigned treatment strategy and attend 1 month follow-up visit

Exclusion Criteria:

- Receiving anti-platelet therapy other than aspirin and clopidogrel

- Receiving anti-coagulation with warfarin or dabigatran

- History of stroke or transient ischemic attack

- Platelet count < 100 000/μL

- Known Bleeding Diathesis

- Hematocrit <30% or >52%

- Severe Liver Dysfunction

- Renal Insufficiency (Creatinine Clearance < 30ml/min)

- Pregnant females